Brief: Heidelberg Pharma: Progress Into Cohort 6 With Proprietary Atac Candidate HDP-101 In Phase I/Iia Multiple Myeloma Study
18/03/2024 06:27
March 18 (Reuters) - Heidelberg Pharma AG HPHA.DE :
* ANNOUNCES PROGRESS INTO COHORT 6 WITH ITS PROPRIETARY ATAC
CANDIDATE HDP-101 IN PHASE I/IIA MULTIPLE MYELOMA STUDY
* WILL BE ADVANCING INTO AN EXPANDED COHORT 6 DOSE
ESCALATION
FOLLOWING SUBMISSION OF A PROTOCOL AMENDMENT TO US FOOD AND DRUG
ADMINISTRATION (FDA) FOR ITS PHASE I/IIA STUDY WITH LEAD ATAC
CANDIDATE HDP-101 FOR TREATMENT OF MULTIPLE MYELOMA
* DATA ACROSS FIRST FOUR COHORTS HAVE DEMONSTRATED HDP-101
TO BE
SAFE AND WELL TOLERATED
Source text for Eikon: ID:nEQ7C9gbWa
Further company coverage: HPHA.DE
(Reporting by Berlin Newsroom)
((berlin.newsroom@thomsonreuters.com;))
Recent news on Heidelberg Pharma AG
See all newsBrief: Heidelberg Pharma And Huadong Medicine Receive Nmpa Approval For Hdp-101 Trial In China
Germany's Heidelberg Pharma H1 sales revenue surges, driven by milestone payments
Brief: Heidelberg Pharma Says Co. And Healthcare Royalty Announce Amendment To Existing Royalty Agreement
Brief: Redhill Biopharma Secures Allowance Of Key Chinese Patent Application For Proprietary COVID-19 Treatment, RHB-107
Brief: Heidelberg Pharma Amends Royalty Financing With Healthcare Royalty